Article Sidebar
Views PDF: 229
ASSESSMENT AND CORRELATION ANALYSIS OF COST EFFECTIVENESS IN THE SWITCHING OF LEVOFLOXACIN FROM PARENTERAL TO ORAL AT HOAN MY SAI GON HOSPITAL
Main Article Content
Abstract
Background: To appropriate conversion from IV to PO antibiotic therapy is necessary, especially with medicines that has high oral bioavailability such as levofloxacin. Objectives: To analyze the cost-effectiveness correlation in the switching of levofloxacin from parenteral to oral in the treatment of respiratory infections. Materials and methods: A retrospective study was performed on 87 medical records from March 15, 2021 to the end of September 30, 2021 at Hoan My Saigon General Hospital. Results: 25/87 cases had antibiotic conversion from parenteral to oral route. The mean age in the study was 70.76 ± 18.32. 72.4% of the patients had an antibiogram with a positive rate of 11.1%. The number of DDD/100 bed days in the switching group was 45.9 and the nonswitching group was 90.9. Most patients received 2 antibiotics combination including levofloxacin with beta-lactams or carbapenems. In the group of 25 cases, 13.57% had a IV to PO switching. Of those, 44% were rationally switched according to the instruction. 100% of patients have successful treatment. The paraclinical indicators showed improvement after treatment in both groups (p<0.05). The cost of antibiotics and the total cost of treatment in the switching group was lower than the other group (p<0.05). Conclusions: The conversion of parenteral to oral levofloxacin has shown a cost-effectiveness advantage. The implementation needs to be followed the instructions of the Ministry of Health to achieve noticeable result.
Article Details
Keywords
Levofloxacin, IV to PO conversion
References
2. Chandrasekhar D, PokkaVV (2019). Cost minimization analysis on IV to oral conversion of antimicrobial agent by the clinical pharmacist intervention. Clinical Epidemiology and Global Health; 7(1), pp.60-65.
3. Cillóniz C, et al (2020). Community-acquired pneumonia in critically ill very old patients: A growing problem, European Respiratory Review; 29(155), 190126.
4. Hariri G, et al (2017). Are third-generation cephalosporins unavoidable for empirical therapy of community-acquired pneumonia in adult patients who require ICU admission? A retrospective study. Annals of Intensive Care;7(1):35. doi: 10.1186/s13613-017-0259-4.
5. Hogan-Murphy D, et al (2019). What Stops Doctors Switching from Intravenous to Oral Antibiotics? Ir Med J;112(8), pp.987.
6. Noel GJ (2009). A Review of Levofloxacin for the Treatment of Bacterial Infections. Clinical Medicine. Therapeutics;1: CMT.S28.
7. Tamma PD, et al (2019). Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia. JAMA Intern Med;179(3), pp.316-323.
8. Tejaswini Y, et al (2018). Practice of Intravenous to Oral Conversion of Antibiotics and its Influence on Length of Stay at a Tertiary Care Hospital: A Prospective Study. Journal of Clinical and Diagnostic Research;12, FC01-FC04.
9. Viswanathan M, et al (2015). Medication therapy management interventions in outpatient settings: A systematic review and meta-analysis. JAMA Intern Med;175(1), pp.76-87.
10. Yen YH (2012). Clinical and economic impact of a pharmacist-managed i.v to p.o conversion service for levofloxacin in Taiwan. International Journal of Clinical Pharmacology and Therapeutics; 50(2), pp.136-141.